Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy
Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an On-going Observational IL-2 Clinical Trial: PROCLAIM
“manuscript in publication”
